Clinician Practice Companion to Address Youth Substance Use
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Boston, United StatesSee the siteAlso in 1 other country, 4 sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Starts
- Jan 2027
- Expected to end
- Dec 2029
- Type of study
- Interventional
- Treatments tested
- Practice Companion
- Record updated
- 7 October 2026
Who can take part
- Age
- 14 years to 24 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Ages 14 to 24 years
- Uses drugs or alcohol (past year)
- Receiving care at a participating study site
Who cannot take part
- Any medical or psychiatric condition causing acute distress or requiring emergency evaluation
- Cognitive limitations or intellectual disabilities that prevent provision of informed consent
- Current membership on a study Community Advisory Board
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 24 years old?
Where in United States
Also in 1 other country, 4 sites
- Adolescent and Young Adult Medicine, Mass General Brigham for ChildrenBoston, United StatesContact: Danya Fast, PhDNot yet recruiting
About the trial
What the trial wants to find out
Substance use, including the use of opioids, cannabis, and other drugs, is common among adolescents and young adults, and overdose has become a leading cause of death among youth in Canada and the United States. Many young people who use substances also experience co-occurring mental health concerns. Evidence-based approaches to youth substance use care exist, including overdose prevention and safety strategies (such as naloxone) and medications for addiction treatment. These approaches remain adult-oriented, however, unevenly implemented in youth-serving settings, and insufficiently centered on the needs and goals of youth and their families.
Read full original descriptionShow less
This study develops and pilot tests a written "practice companion" that helps clinicians and other trusted adults provide developmentally appropriate substance use care to youth ages 14 to 24 in hospital and community settings. The practice companion offers practical, easy-to-use guidance organized by substance and by pattern of use. It addresses cannabis and other substances that youth commonly use and that clinicians frequently seek support with, alongside a strong focus on overdose prevention through its core elements: naloxone, other safety strategies, overdose prevention and safety education, and medications for opioid use disorder. It also attends to co-occurring mental health needs and to how poverty, housing instability, and other social circumstances shape substance use and access to care.
The research team will first interview youth who use substances, their families and caregivers, and clinicians to learn how each element of care should be adapted for young people. The team will then produce the practice companion and pilot test it with 60 youth across three sites, in British Columbia, Québec, and Massachusetts. After receiving care guided by the practice companion, youth will complete an interview about whether the care was relevant, useful, appropriate, and acceptable. Families and clinicians will also be interviewed to assess how feasible, sustainable, and faithful to its design the practice companion is in practice.
Throughout the study, the team will work closely with youth and families who have lived experience through a community-based participatory research approach that includes Community Advisory Boards. Findings will guide a larger future study of the practice companion's effectiveness.
The group in the trial
- Practice CompanionTreatment being tested
Youth ages 14 to 24 who use substances receive developmentally appropriate substance use care from a clinician (or other trained provider) using the practice companion. Depending on individual needs, the provider offers guidance across the practice companion's elements, including overdose prevention (naloxone, other safety strategies, overdose prevention and safety education, and medications for addiction treatment), support around cannabis and other substance use, and attention to co-occurring mental health, delivered through non-stigmatizing, youth- and family-centered scripts and referral guidance.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Fit questions
- Built from NCT07725289, who can take part
- Record updated
- 7 October 2026